Publications

Detailed Information

The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial

DC Field Value Language
dc.contributor.authorPark, Kyungil-
dc.contributor.authorChung, Woo-Young-
dc.contributor.authorSeo, Jae-Bin-
dc.contributor.authorKim, Sang-Hyun-
dc.contributor.authorKim, Myung-A-
dc.contributor.authorPark, Young-Bae-
dc.contributor.authorZo, Joo-Hee-
dc.date.accessioned2012-06-28T02:04:52Z-
dc.date.available2012-06-28T02:04:52Z-
dc.date.issued2010-12-20-
dc.identifier.citationTRIALS; Vol.11 ; -ko_KR
dc.identifier.issn1745-6215-
dc.identifier.urihttps://hdl.handle.net/10371/77723-
dc.description.abstractBackground: Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration with saline are being prescribed to prevent renal deterioration in these high risk patients, their efficacy is not clearly defined and debatable. Therefore additional prophylactic pretreatments are needed. Methods/Design: The present study aims to investigate differences in occurrence of CIN after sarpogrelate premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) routine treatment without sarpogrelate, and (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the occurrence of CIN during 4 weeks after receiving contrast agent. Discussion: As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option.ko_KR
dc.language.isoenko_KR
dc.publisherBIOMED CENTRAL LTDko_KR
dc.titleThe prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trialko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박경일-
dc.contributor.AlternativeAuthor정우영-
dc.contributor.AlternativeAuthor서재빈-
dc.contributor.AlternativeAuthor김상현-
dc.contributor.AlternativeAuthor조주희-
dc.contributor.AlternativeAuthor김명아-
dc.contributor.AlternativeAuthor박영배-
dc.identifier.doi10.1186/1745-6215-11-122-
dc.citation.journaltitleTRIALS-
dc.description.citedreferenceMasuda M, 2007, AM J CARDIOL, V100, P781, DOI 10.1016/j.amjcard.2007.03.098-
dc.description.citedreferenceRecio-Mayoral A, 2007, J AM COLL CARDIOL, V49, P1283, DOI 10.1016/j.jacc.2006.11.034-
dc.description.citedreferenceWeisbord SD, 2006, J AM SOC NEPHROL, V17, P2871, DOI 10.1681/ASN.2006030301-
dc.description.citedreferenceStacul F, 2006, AM J CARDIOL, V98, p59K, DOI 10.1016/j.amjcard.2006.01.024-
dc.description.citedreferenceRudnick MR, 2006, CLEV CLIN J MED, V73, P75-
dc.description.citedreferenceMerten GJ, 2004, JAMA-J AM MED ASSOC, V291, P2328-
dc.description.citedreferenceDoggreu SA, 2003, EXPERT OPIN INV DRUG, V12, P805-
dc.description.citedreferenceHayashi T, 2003, ATHEROSCLEROSIS, V168, P23, DOI 10.1016/S0021-9150(03)00054-6-
dc.description.citedreferenceKay J, 2003, JAMA-J AM MED ASSOC, V289, P553-
dc.description.citedreferenceNIKOLSKY E, 2003, REV CARDIOVASC ME S5, V4, pS10-
dc.description.citedreferenceFUJITA M, 2003, AM HEART J, V145, pE16-
dc.description.citedreferenceTakahashi T, 2002, DIABETES RES CLIN PR, V58, P123-
dc.description.citedreferenceIchiyanagi N, 2002, J UROLOGY, V168, P303-
dc.description.citedreferenceRihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33-
dc.description.citedreferenceGruberg L, 2000, J AM COLL CARDIOL, V36, P1542-
dc.description.citedreferenceMiyata K, 2000, J CARDIOVASC PHARM, V35, P294-
dc.description.citedreferenceSharma SK, 1999, J PHARMACOL EXP THER, V290, P1475-
dc.description.citedreferenceErley CM, 1999, NEPHROL DIAL TRANSPL, V14, P1146-
dc.description.citedreferenceOgawa S, 1999, CLIN EXP PHARMACOL P, V26, P461-
dc.description.citedreferenceMorcos SK, 1999, EUR RADIOL, V9, P1602-
dc.description.citedreferenceMcCullough PA, 1997, AM J MED, V103, P368-
dc.description.citedreferenceIshimura E, 1997, NEPHRON, V76, P227-
dc.description.citedreferenceKanai H, 1997, J LAB CLIN MED, V129, P557-
dc.description.citedreferenceRudnick MR, 1997, SEMIN NEPHROL, V17, P15-
dc.description.citedreferenceTOPOL E, 1993, NEW ENGL J MED, V329, P673-
dc.description.citedreferenceHEYMAN SN, 1991, KIDNEY INT, V40, P632-
dc.description.citedreferenceHARA H, 1991, THROMB HAEMOSTASIS, V66, P484-
dc.description.citedreferenceHARA H, 1991, ARZNEIMITTEL-FORSCH, V41-1, P616-
dc.description.citedreferenceHEYMAN SN, 1988, J CLIN INVEST, V82, P401-
dc.description.citedreferenceKATZBERG RW, 1977, INVEST RADIOL, V12, P381-
dc.description.tc1-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share